Metastatic Cancer
Conditions
Brief summary
The aim of this study is to characterize the genetic and cellular immunological parameters of metastatic digestive cancer patients having short and long responses to chemotherapy.
Interventions
blood and tissue samples
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For all patients: * signed written informed consent For cohort A: * patient with metastatic colorectal cancer with first-line therapy by chemotherapy +/- surgery and with a disease-free survival \> or = at 20 months * Ct-scan realized in the previous 4 weeks and showing no progression according to the Recist criteria v1.1 For cohort B: * patient treated for metastatic colorectal cancer and chemotherapy responder (obtention of an objective response according to the Recist criteria V1.1 in first-line therapy), with a disease-free survival \< 10 months (disease progression must be confirmed by CT scan evaluation according to Recist v1.1 criteria) For cohort C: * patients with no metastatic rectum cancer in complete remission after chemotherapy and/or radiotherapy For cohort D: * patients with metastatic or locally advanced cancer in complete remission after treatment, non eligible in the other cohorts
Exclusion criteria
For all patients: * patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study * patient with a neurodegenerative disease * patient under guardianship, curator or under the protection of justice
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| frequency of peripheral T cell immune responses in the presence of antigenic peptides associated with digestive cancer | at inclusion | — |
| progression-free survival | within 5 years after the inclusion | time interval between the date of inclusion and the date of first progression or death from any cause. |
Countries
France
Outcome results
None listed